logo
Plus   Neg
Share
Email

Gainers & Losers Of June 29: OBSV, SBBP, EIGR, BIOS, PBMD...

June29-062917.jpg

The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of June 29, 2017.

GAINERS

1. ObsEva SA (OBSV)

Gained 27.12% to close Thursday's (June 29) trading at $7.50.

News: The Company announced that it will be making presentations related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) development programs at the European Society of Human Reproduction and Embryology (ESHRE) 2017 Annual Meeting, taking place July 2-5.

The results from a phase II clinical trial, dubbed IMPLANT, which assessed pregnancy and live birth rates after single oral administration of the Company's investigational novel oxytocin antagonist, Nolasiban indicate a potential absolute increase of about 10 percent, or greater compared to placebo in pregnancy and live birth rates after administration of a single oral dose of Nolasiban before embryo transfer, according to Herman Tournaye, the principal investigator for the IMPLANT study.

Up next:

The Company expects to begin a phase II trial of yet another drug candidate OBE022 in pregnant women with preterm labor later this year.

2. Strongbridge Biopharma plc (SBBP)

Gained 19.51% to close Thursday's trading at $7.34.

News: No news

Pipeline:

Strongbridge's pipeline includes RECORLEV for treating endogenous Cushing's syndrome under phase III trial, and Veldoreotide for treatment of patients with acromegaly under phase II testing.

Recent event:

The Company completed its target enrollment of 90 patients in its phase III study of RECORLEV for the treatment of endogenous Cushing's syndrome, dubbed SONICS, as recently as June 27, 2017.

Near-term catalyst:

The top-line results from the SONICS study are expected in the second quarter of 2018.

3. Conatus Pharmaceuticals Inc. (CNAT)

Gained 10.71% to close Thursday's trading at $6.20.

News: H.C. Wainwright analyst Ed Arce reiterated his 'Buy' rating and $18 target price on the stock.

Recent event:

On June 26, 2017, the FDA granted Orphan Drug Designation to Conatus' preclinical drug candidate IDN-7314 for the treatment of primary sclerosing cholangitis (PSC), a disease affecting bile ducts in the liver which can lead to cirrhosis and liver failure.

Pipeline:

The company's lead compound is Emricasan, a first-in-class, orally active caspase protease inhibitor, that interrupts the progression of liver disease by reducing the activity of enzymes that mediate inflammation and cell death.

Emricasan is under four phase IIb clinical trials namely,

-- A phase IIb trial of Emricasan, in post-orthotopic liver transplant (POLT) recipients, dubbed POLT-HCV-SVR. Top-line results are expected in the first half of 2018.
-- A phase IIb trial of Emricasan in reducing hepatic venous pressure gradient in patients with compensated or early decompensated liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), and severe portal hypertension, dubbed ENCORE-PH. Top-line results from this trial are expected in 2018.
-- A phase IIb clinical trial of Emricasan evaluating potential improvements in fibrosis and steatohepatitis in patients with fibrosis caused by NASH, dubbed ENCORE-NF. Top line results are expected in the first half of 2019.
-- A phase IIb clinical trial of Emricasan in NASH cirrhosis patients, dubbed ENCORE-LF. Top-line results are expected in 2019.

4. Eiger Biopharmaceuticals Inc. (EIGR)

Gained 10.71% to close Thursday's trading at $7.75.

News: The Company has agreed to sell to Theragene Pharmaceuticals Inc., a private biotechnology company, a non-strategic asset, Mydicar.

Theragene will make a total upfront payment of $3.1 million to Eiger and pre-specified clinical and regulatory milestones totaling $15 million, royalties on net sales, and sublicensing and milestone fees.

Theragene has committed to repurchase $1.35 million of the common stock paid to Eiger upon the closing of a financing raise of $4 million or more. Additional financial terms have not been disclosed.

5. Minerva Neurosciences Inc. (NERV)

Gained 10.06% to close Thursday's trading at $8.75.

News: No news

Recent event: On June 28, 2017, the Company priced its public offering of 5 million shares of its common stock at $7.75 each.

Proceeds to Minerva from the offering are expected to be approximately $38.75 million. The offering is expected to close on or about July 5th, 2017, subject to customary closing conditions.

6. Presbia PLC (LENS)

Gained 9.38% to close Thursday's trading at $2.41.

News: No news

Pipeline:

The Company's lead product candidate is Presbia Flexivue Microlens, a revolutionary optical lens implant for treating presbyopia, the age-related loss of near vision.

Near-term catalyst:

The Company expects to seek approval of Presbia Flexivue Microlens in the fourth quarter of this year.

LOSERS

1. BioScrip Inc. (BIOS)

Lost 12.71% to close Thursday's trading at $2.61.

News: The Company has entered into an agreement with a group of note purchasers, led by funds managed by Ares Management, L.P. to refinance its existing senior credit facility and priming credit agreement.

Under the agreement, the Company entered into a $200 million first lien note facility and a $110 million second lien note facility. The Company will receive $300 million from these facilities. Also as part of the agreement, the Company will receive a $16 million common stock investment, and will issue common stock warrants with a 10-year term.

Cash on hand at close will be in excess of $40 million, and combined with $10 million of additional availability on the second lien note, the Company's liquidity will be in excess of $50 million.

2. Cascadian Therapeutics Inc. (CASC)

Lost 12.44% to close Thursday's trading at $3.73.

News: No news

Pipeline:

The Company's lead drug candidate is Tucatinib, under pivotal trial in patients with locally advanced or metastatic HER2-positive breast cancer, dubbed HER2CLIMB.
Enrollment in this study is expected to be completed by mid-2019.

As for the regulatory strategy of Tucatinib for Europe is concerned, the Company plans to seek scientific advice from European Medicines Agency in the second half of this year.

Tucatinib is designated orphan drug by the FDA for the treatment of breast cancer patients with brain metastases.

3. Bellicum Pharmaceuticals Inc. (BLCM)

Lost 9.72% to close Thursday's trading at $12.02.

News: No news

Pipeline:

The company's lead product candidate is BPX-501, which is being evaluated in multiple phase 1/2 clinical trials in adults and pediatric patients with leukemias, lymphomas, and genetic blood diseases in the U.S. and Europe.

Recent event:

On March 23, 2017, the Company announced data from its ongoing Phase 1/2 clinical trial of BPX-501 plus Rimiducid in a cohort of pediatric patients with acute leukemias, highlighting high success rate of haploidentical transplants, with low incidence of disease relapse and uncontrolled Graft versus Host Disease.

4. Aptevo Therapeutics Inc. (APVO)

Lost 7.34% to close Thursday's trading at $2.02.

News: No news

Pipeline:

The Company has two clinical drug candidates - MOR209/ES414 monotherapy in patients with metastatic castration-resistant prostate cancer, under phase I trial, and Otlertuzumab for chronic lymphocytic leukemia, under phase II study.

5. Prima BioMed Ltd. (PBMD)

Lost 7.30% to close Thursday's trading at $2.16.

News: The Company has entered into a securities purchase agreement with certain accredited investors to purchase 2.63 million of its American Depositary Shares at a price of US$1.90 per ADS in a registered direct offering.

The total gross proceeds from the offering are expected to be about US$5.0 million (equivalent to approximately AU$6.5 million).

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>